摘要
有许多临床问题,即使是训练有素的医生也不容易回答。常用的诊断工具,是以评估认知功能障碍的神经退行性疾病为基础建立的临床标准。然而,疾病之间的鉴别诊断是困难的,特别是在早期阶段或非典型变种。当它仍然有可能使用一个适当的治疗时,这尤为重要。 为了解决这个问题,医生需要获得诊断测试的军工厂,如神经功能成像,允许更高的特异性临床评价。然而,诊断测试的可靠性从一个到下一个可能会有所不同,因此,一个给定的调查的诊断的有效性,必须估计通过从“真实”标准的“金标准”或基准测试比较获得的结果。虽然病理分析在广泛的疾病中被认为是的金标准,但是它不能被应用到神经系统过程。其他的方法可以提供解决方案,包括临床患者随访,创建一个数据银行或使用计算机辅助诊断算法。 在这篇文章中,我们讨论了与诊断效度分析相关不同的方法程序的发展和以使用碘-123-碘氟烷-单光子发射计算机化断层显像为基础介绍的运动障碍患者研究的一个自身经历。本章的目的是考虑到特定的神经退行性疾病的问题,从医生的角度来看探讨问题。
关键词: 阿尔茨海默病,计算机辅助诊断系统,痴呆,诊断准确,机器学习,神经成像,支持向量机。
Current Alzheimer Research
Title:Diagnosis of Neurodegenerative Diseases: The Clinical Approach
Volume: 13 Issue: 5
Author(s): Manuel Gómez-Río, Manuel Moreno Caballero, Juan Manuel Górriz Sáez and Adolfo Mínguez-Castellanos
Affiliation:
关键词: 阿尔茨海默病,计算机辅助诊断系统,痴呆,诊断准确,机器学习,神经成像,支持向量机。
摘要: There are a number of clinical questions for which there are no easy answers, even for welltrained doctors. The diagnostic tool commonly used to assess cognitive impairment in neurodegenerative diseases is based on established clinical criteria. However, the differential diagnosis between disorders can be difficult, especially in early phases or atypical variants. This takes on particular importance when it is still possible to use an appropriate treatment.
To solve this problem, physicians need to have access to an arsenal of diagnostic tests, such as neurofunctional imaging, that allow higher specificity in clinical assessment. However, the reliability of diagnostic tests may vary from one to the next, so the diagnostic validity of a given investigation must be estimated by comparing the results obtained from “true” criteria to the “gold standard” or reference test. While pathological analysis is considered to be the gold standard in a wide spectrum of diseases, it cannot be applied to neurological processes. Other approaches could provide solutions, including clinical patient follow-up, creation of a data bank or use of computer-aided diagnostic algorithms.
In this article, we discuss the development of different methodological procedures related to analysis of diagnostic validity and present an example from our own experience based on the use of I-123-ioflupane-SPECT in the study of patients with movement disorders. The aim of this chapter is to approach the problem of diagnosis from the point of view of the clinician, taking into account specific aspects of neurodegenerative disease.
Export Options
About this article
Cite this article as:
Manuel Gómez-Río, Manuel Moreno Caballero, Juan Manuel Górriz Sáez and Adolfo Mínguez-Castellanos , Diagnosis of Neurodegenerative Diseases: The Clinical Approach, Current Alzheimer Research 2016; 13 (5) . https://dx.doi.org/10.2174/1567205013666151116141603
DOI https://dx.doi.org/10.2174/1567205013666151116141603 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design G-Lymphatic, Vascular and Immune Pathways for Aβ Clearance Cascade and Therapeutic Targets For Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening In vitro Antioxidant and Acetylcholinesterase Inhibitory Activities of Fractions from Centella asiatica (Linn.) Extract
Current Bioactive Compounds Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders Potential Enzymatic Targets in Alzheimer’s: A Comprehensive Review
Current Drug Targets Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy Protein Interaction Studies for Understanding the Tremor Pathway in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Integrated Genomic Analysis Revealed Associated Genes for Alzheimer’s Disease in APOE4 Non-Carriers
Current Alzheimer Research Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer’s Disease
Current Alzheimer Research CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Voice Markers of Lexical Access in Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Attentional Set-Shifting in Rodents: A Review of Behavioural Methods and Pharmacological Results
Current Pharmaceutical Design Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research Differences in Relative Levels of 88 microRNAs in Various Regions of the Normal Adult Human Brain
MicroRNA Can Acetylcholinesterase Serve as a Target for Developing More Selective Insecticides?
Current Drug Targets Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Editorial from Editor-in-Chief [Cheyne-Stokes: A Flashback to the 19th Century]
Current Respiratory Medicine Reviews Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging